April 28, 2009 -- Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market its darifenacin hydrobromide extended-release 7.5 mg and 15 mg product prior to the expiration of a patent owned by Novartis AG.
The details can be read here.
No comments:
Post a Comment